9th Annual Mood Disorders Summit 2022

Join us for the live 9th Annual Mood Disorders Summit 2022, which will be presented online in a virtual format. Now in its 9th year, this free comprehensive 2-day conference will explore state of the art diagnostic and therapeutic issues in patients with mood disorders. Register early to secure your seat!

To Register: On the Event Dates page, click Webinar/Online. On the next screen, please click the blue Register button in the upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the event.


*Subject to change

All times are in Eastern Time.

Day 1 - Friday, November 11, 2022

9:55 AM - 10:00 AM: Opening Remarks by Moderator - Joseph F. Goldberg, MD

10:00 AM - 11:00 AM: An Evidence-Based Approach to Treating Bipolar Depression - Joseph F. Goldberg, MD
This session will provide treatment pearls for bipolar depression and focus on individualizing treatment plans based on patient–specific characteristics.

-Break (5 min)-

11:05 AM - 12:05 PM: Non-CME Educational Talk
Sponsored by AbbVie
The Management of Bipolar I Depression
Presenter: Greg W. Mattingly, MD

-Break (5 min)-

12:10 PM - 1:10 PM: The Evolving Landscape of Digital Therapeutics for Major Depressive Disorder - Nicholas C. Jacobson, PhD and Joseph F. Goldberg, MD
Healthcare-related technology, or digital health, is advancing at rapid pace and becoming more prevalent in use. This session will inform healthcare professionals on the latest technology, what is on the horizon, and how to integrate digital therapeutic interventions into the treatment of patients with major depressive disorder.

-Break (30 min)-

1:40 PM - 2:40 PM: Non-CME Educational Talk
Sponsored by Intra-Cellular Therapies, Inc.
Clinical Evidence Supporting the Use of a Once-Daily Atypical Antipsychotic for Bipolar Depression: Bipolar I or II
Presenter: Roger S. McIntyre, MD, FRCPC

-Break (5 min)-

2:45 PM - 3:45 PM: Novel Mechanisms for the Treatment of MDD - Sanjay J. Mathew, MD
This session will provide an overview of the rationale for breaking away from a focus on monoamine modulation in major depressive disorder and treatment-resistant depression. Attendees will come away from the presentation with knowledge on novel and emerging drugs with differing mechanisms.

-Break (15 min)-

4:00 PM - 5:00 PM: Reproductive Psychiatry: PMDD, Perinatal Mood Disorders, and Peri/Postmenopausal Depression Plus Comorbidities – Complex Interactions Require Comprehensive Assessment and Treatment - Anita Clayton, MD
This session will review symptoms and diagnosis of mood disorders associated with reproductive life events. The importance of evaluation for and recognition of specific medical and psychiatric comorbidities impacting management will be discussed.

-Break (5 min)-

5:05 PM - 6:05 PM: Far Out? Understanding Psychedelic Mechanisms and Their Potential Impact on Mood Disorders - Robin Carhart-Harris, PhD
This session will go over the current understanding of the mechanism of action of psychedelics and how that translates to an impact on brain functioning and mood in psychiatric patients. Key research that has influenced the utility of psychedelics in psychiatric care will be discussed to enhance understanding of what the future holds for this up-and-coming field.

6:05 PM - 6:10 PM: Closing Remarks - Joseph F. Goldberg, MD


Day 2 - Saturday, November 12, 2022

9:55 AM - 10:00 AM: Opening Remarks by Moderator - Greg W. Mattingly, MD

10:00 AM - 11:00 AM: Recognizing and Managing Tardive Dyskinesia in Patients With Mood Disorders - Leslie Citrome, MD, MPH
This session will discuss practical assessment tips and evidence-based treatment strategies for your patients with mood disorders and tardive dyskinesia, including the impact of patient insight on management considerations.

-Break (5 min)-

11:05 AM - 12:05 PM: Non-CME Educational Talk
Sponsored by Otsuka America Pharmaceutical, Inc. and Lundbeck
The Efficacy and Safety Profile of an Adjunctive Therapy for Adult Patients with Major Depressive Disorder (MDD)
Presenter: Ilan Melnick, MD

-Break (5 min)-

12:10 PM - 1:10 PM: Calming Down: Addressing Acute Agitation in Bipolar Disorder - Joseph F. Goldberg, MD
Acute agitation is common in patients with bipolar disorder, including bipolar I manic, mixed, or depressed episodes. This session will focus on the causes and differential diagnosis of acute agitation in patients with bipolar disorder and review evidenced-based guidelines and first-line pharmacotherapies for its management.

-Break (30 min)-

1:40 PM - 2:40 PM: Meeting the Unmet Needs in MDD Care - Greg W. Mattingly, MD
This session will review the role of atypical antipsychotics as augmentation therapy for patients with major depressive disorder, including discussion of medication factors to consider when tailoring treatment to the individual patient.

-Break (5 min)-

2:45 PM - 3:45 PM: It’s a Gut Feeling: The Role of Gut Microbiota in Mood Disorders - Sarkis Mazmanian, PhD
We are all well aware of the role of nutrition in physical maladies, but the role of the gut in psychiatric illnesses is only beginning to be understood. In this session, learn how the gut–brain connection can influence mood disorders—both positively and negatively—and how to apply this knowledge to your practice.

-Break (15 min)-

4:00 PM - 5:00 PM: Symptom in Search of a Cure: Neurobiologic Basis and Treatment of Anhedonia in Mood Disorders - Vladimir Maletic, MD
Anhedonia is a cardinal symptom in both unipolar and bipolar depression that is a predictor of poor treatment outcomes and increases risk for suicidal ideation. This session will examine the latest evidence related to pathophysiology of anhedonia in depression, as well as current and emerging treatment strategies.

5:00 PM - 5:05 PM: Closing Remarks - Greg W. Mattingly, MD


Date / Time
Event Details


Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Greg W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
St Louis, Missouri
St Charles Psychiatry Associates
St Charles, Missouri

Robin Carhart-Harris, PhD

Department of Neurology
University of California, San Francisco
San Francisco, California

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Anita Clayton, MD

David C. Wilson Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
University of Virginia School of Medicine
Charlottesville, Virginia

Nicholas C. Jacobson, PhD

Assistant Professor
Biomedical Data Science, Psychiatry, and Computer Science
Geisel School of Medicine
Dartmouth College
Lebanon, New Hampshire

Vladimir Maletic, MD

Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

Sanjay J. Mathew, MD

Professor and Vice Chair for Research
Psychiatry and Behavioral Sciences
Baylor College of Medicine
Houston, Texas

Sarkis Mazmanian, PhD

Luis and Nelly Soux Professor of Microbiology
Division of Biology and Biological Engineering
California Institute of Technology
Pasadena, California

Roger S. McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Ilan Melnick, MD

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of mood disorders.

Target Audience
This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, pharmacists, social workers, and psychologists engaged in the care of patients with mood disorders.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review and assess the latest advances in treatment options for patients with mood disorders
  • Develop individualized treatment strategies for optimal outcomes in patients with mood disorders
  • Discuss best practices and treatment guidelines to improve patient care


*Credits/Contact Hours are subject to change

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 10.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 10.0 contact hours, including 9.0 hours of pharmacology credit.

Continuing Pharmacy Education

CCO designates this continuing education activity for 10.0 contact hours (1.0 CEUs) of the Accreditation Council for Pharmacy Education. UAN will be specific to each topic.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 10.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Psychologist Continuing Education

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity will offer 10.0 continuing education credits for psychologists.

Social Work Continuing Education

As a Jointly Accredited Organization, Clinical Care Options, LLC (CCO) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. CCO maintains responsibility for this course. Social workers completing this course will receive up to 10.0 continuing education credits.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.